Patent intelligence · US
US 9603906
Inhalable liquid formulations of DNase I
Inhalable liquid formulations of DNase I
Patent details — US 9603906
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 28, 2017
- Expiration
- Mar 23, 2037
- Applicant
- Protalix Ltd.
- Claims
- 19
- CPC classes
- A61K, A61K33/06, A61K33/14, A61K38/465
Quick answer
US 9603906 (Inhalable liquid formulations of DNase I) is held by Protalix Ltd.. Status: granted. Granted Mar 28, 2017. Expires Mar 23, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Protalix Ltd.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K33/06, A61K33/14, A61K38/465, A61K38/47, A61K45/06
More from Protalix Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12385026
Stabilized alpha-galactosidase and uses thereof
granted -
US 12194079
Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase
granted -
US 11814657
Modified DNase and uses thereof
granted -
US 11225648
Modified DNase and uses thereof
granted -
US 10870842
Stabilized alpha-galactosidase and uses thereof
granted -
US 10730925
Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
granted -
US 10280414
Stabilized α-galactosidase and uses thereof
granted -
US 10087232
Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy
granted
Frequently asked questions
What is US patent 9603906?
US 9603906 (Inhalable liquid formulations of DNase I) is held by Protalix Ltd.. Status: granted. Granted Mar 28, 2017. Expires Mar 23, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9603906?
Protalix Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 22 pharmaceutical patents for this assignee.
When does US 9603906 expire?
Our index shows an expiration date of Mar 23, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.